Answers are grounded in this paper and cite their sources.
Descriptive cross-sectional study evaluates antibiotic efficacy in Escherichia coli strains, suggesting quality variation among brands.
Introduction: Antibiotics play a crucial role in reducing morbidity and mortality from infectious diseases worldwide. The objective of this study was to evaluate the MIC of beta-lactams and fluoroquinolones marketed in pharmacies in the city of Lubumbashi. Material and methods: This is a descriptive cross-sectional study conducted from December 22, 2024 to March 10, 2025. The study involved community-acquired Escherichia coli strains isolated from urinary tract infections; as well as 4 antibiotics from 3 different pharmaceutical companies operating in Lubumbashi: ciprofloxacin; norfloxacin; amoxicillin + clavulanic acid and ceftriaxone. Results: The pharmaceutical firm 1 has revealed that the Escherichia coli strains had MICs within the normal range for amoxicillin + clavulanic acid (5 strains/5); norfloxacin (3 strains/2). For company 2, amoxicillin + clavulanic acid and norfloxacin had MICs within the normal range for all 5 strains. And for company 3, all 5 strains had MICs within the normal range for amoxicillin + clavulanic acid. The MBC/MIC report of antibiotics from different pharmaceutical firms, for which the MICs were within CLSI standards, revealed that the CMIs were bactericidal. Conclusion: The antibiotics from pharmaceutical company 2 performed well compared to those from other companies; followed by the antibiotics from pharmaceutical company 1 and those from pharmaceutical company 3.
No takes yet. Share an insight, caveat, or question.
Kamona et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: